Skip to main content

Ortho Clinical Diagnostics to Offer Sphingotec Heart Failure Assay

NEW YORK (360Dx) – Ortho Clinical Diagnostics has signed an agreement to use Sphingotec's Sphingotest Bio-ADM heart failure immunoassay on its automated Vitros immunodiagnostics and integrated systems, the companies announced today.

The CE-marked Sphingotest Bio-ADM is designed to measure plasma levels of biologically active adrenomedullin, a soluble peptide hormone involved in vasodilation and a clinically validated biomarker for monitoring residual congestion in patients hospitalized with acute heart failure. Hennigsdorf, Germany-based Sphingotec is also evaluating adrenomedullin as a biomarker for shock in sepsis patients.

"Ortho is committed to the continued expansion of our menu offerings, through both internal research and development programs and strategic collaborations," Ortho COO Robert Yates said in a statement. "Our strategic agreement regarding the Sphingotest Bio-ADM assay positions us to bring this novel cardiac biomarker to a broad range of clinical labs around the world."

Specific terms of the deal were not disclosed.